QiHong prevents death in coxsackievirus B3-induced murine myocarditis through inhibition of virus attachment and penetration

Experimental Biology and Medicine

Volumn 232, Issue 11, 2007, Pages 1441-1448

  Song, Xiaodong ^a   Liu, Zhe ^a   Wang, Hu ^a   Xin, Ying ^a   Wang, Xiaojian ^a   Chen, Jingzhou ^a   Shi, Yi ^a   Zhang, Channa ^a   Hui, Rutai ^a,b  

^a FUWAI HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Coxsackieviruses; Herbal medicine; QiHong; Viral myocarditis

Indexed keywords

ASTRAGALI EXTRACT; PLANT EXTRACT; QIHONG; RHADIOLA ROSEA EXTRACT; RIBAVIRIN; SODIUM 3' [1 (PHENYLAMINO CARBONYL) 3,4 TETRAZOLIUM] BIS(4 METHOXY 6 NITRO)BENZENE SULFONIC ACID; SOPHORA FLAVESCENS EXTRACT; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; IN VIVO STUDY; MALE; MOUSE; MYOCARDITIS; NONHUMAN; SURVIVAL; VIRUS ADSORPTION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; COXSACKIEVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; NECROSIS; RIBAVIRIN; VERO CELLS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

COXSACKIEVIRUS; MURINAE; MUS; SOPHORA FLAVESCENS;

EID: 36849035433     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0704-RM-110     Document Type: Article

References (19)

1. Woodruff JF. Viral myocarditis: a review. Am J Pathol 101: 427-479, 1980.
2. Drory Y, Turetz Y, Hiss Y, Lev B, Fisman EZ, Pines A, Kramer MR. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 68:1388-1392, 1991.
3. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Circulation 99:1091-1100, 1999.
4. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47:525-531, 1981.
5. Feldman AM, McNamara D. Myocarditis. N Engl J Med 343:1388-1398, 2000.
6. Bean B. Antiviral therapy: current concept and practices. Clin Microbiol 5:146-182, 1992.
7. Zoulim F, Haem J, Ahmed SS, Chossegros P, Habersetzer F, Chevallier M, Bailly F, Trepo C. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 5:193-198, 1998.
8. The Pharmacopoeia Committee. Chinese Pharmacopoeia (Vol I). Beijing: Chinese Chemical Industry Press; 2005.
9. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR. New soluble- formazan assay for HIV-1 cytopathic effects: application to highflux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 81:577-586, 1989.
10. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti- HIV compounds. J Virol Methods 20:309-321, 1988.
11. Logu AD, Loy G, Pellerano ML, Bonsignore L, Schivo ML. Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularis essential oil. Antiviral Res 48:177-185, 2000.
12. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833, 1998.
13. Boulware SL, Bronstein JC, Nordby EC, Weber PC. Identification and characterization of benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res 51:111-125, 2001.
14. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J Infect Dis 175:697-700, 1997.
15. Muckelbauer JK, Kremer M, Minor I, Diana G, Dutko FJ, Groarke J, Pevear DC, Rossmann MG. The structure of coxsackievirus B3 at 3.5 Angstrom resolution. Structure 3:653-667, 1995.
16. He Y, Chipman PR, Howitt J, Bator CM, Whitt MA, Baker TS, Kuhn RJ, Anderson CW, Freimuth P, Rossmann MG. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol 8:874-878, 2001.
17. Rossmann MG. The canyon hypothesis. Viral Immunol 2:143-161, 1989.
18. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong J, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323, 1997.
19. Shafren DR, Williams DT, Barry RD. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirusadenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 71:9844-9848, 1997.